Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.
On March 5, 2026, BriaCell Therapeutics Corp. held its Annual General and Special Meeting of Shareholders, with 3,502,695 of 7,250,487 eligible common shares represented, constituting a quorum. Shareholders ratified the appointment of MNP LLP as the company’s auditors and authorized the board to set the auditors’ remuneration and engagement terms.
At the same meeting, six directors, including Dr. Jane Gross and Mr. Jamieson Bondarenko, were re-elected to serve until the next annual and special meeting or until successors are appointed. Shareholders also re-approved BriaCell’s omnibus equity incentive plan, reinforcing the company’s ability to grant equity-based compensation as a tool for retaining talent and aligning management incentives with shareholder interests.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$5.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn with likely ongoing financing needs). Technicals are mixed with some shorter-term strength but negative MACD and a price still far below the 200-day average. Valuation contributes limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a biotechnology company focused on developing novel cancer immunotherapies, principally targeting breast cancer. The company operates in the life sciences sector, advancing targeted therapeutic platforms aimed at improving treatment options for oncology patients and enhancing long-term shareholder value through clinical and regulatory progress.
Average Trading Volume: 27,847
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$37.49M
See more insights into BCT stock on TipRanks’ Stock Analysis page.